Status:

COMPLETED

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Lead Sponsor:

Vanderbilt-Ingram Cancer Center

Conditions:

Adult Stem Cell Hematopoetic Transplant

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Hypothesis 1: The safety profile in adult allogeneic stem cell hematopoietic transplant (SCT) recipients after high dose (HD) trivalent inactivated influenza vaccine (TIV) will not be significantly di...

Eligibility Criteria

Inclusion

  • Allogeneic hematopoietic stem cell transplant recipients who are \>6 post-transplant
  • greater than or equal to 18 years of age
  • Available for duration of study
  • If patients are on immunosuppressive therapy for treatment of graft versus host disease (GVHD): only those on stable doses for at least 4 weeks or on tapering doses will be eligible.

Exclusion

  • History of hypersensitivity to previous influenza vaccination or hypersensitivity to eggs/egg protein
  • History of Guillain-Barre syndrome
  • Evidence of hematologic malignancy or disease relapse post-transplant (mixed chimerisms and molecular evidence of disease is permitted)
  • Non-allogeneic (e.g. autologous) hematopoietic SCT recipients
  • History of receiving 2011 - 2012 influenza vaccine
  • History of proven influenza disease after September 1, 2011.
  • Pregnant females
  • Have any condition that would, in the opinion of the site investigator, place them at an unacceptable risk of injury or render them unable to meet the requirements of the protocol
  • Have any condition that the investigator believes may interfere with successful completion of the study
  • Platelet count less than 50,000 cells/μL
  • History of known infection with HIV, Hepatitis B or Hepatitis C
  • History of known latex hypersensitivity

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2012

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT01215734

Start Date

October 1 2010

End Date

September 1 2012

Last Update

March 8 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt-Ingram Cancer Center, Clinical Trials Information Program

Nashville, Tennessee, United States, 37232